Citi opened a “90-day positive catalyst watch” on shares of Zimmer Biomet (ZBH) while keeping a Neutral rating on the name with a $120 price ...

Zimmer Biomet had a strong 2024, bolstering its product lines and staying on top of orthopedic medtech trends.

WARSAW, Ind., Dec. 4, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced U.S. Food and Drug Administration (FDA) 510(k ...

Zimmer Biomet has scored an FDA clearance for a new component of its total knee replacement offering, aimed at patients who may be sensitive to certain metals or bone cement. The Persona SoluTion ...

Pfizer, seeking to equalize outcomes, taps Patrick Dempsey to shepherd cancer patients to resources Schwarzenegger, who has had a hip replaced, said Zimmer Biomet’s focus on maximizing mobility ...

Since its initial launch in England in 2004, the Oxford Cementless Partial Knee has become the preferred partial knee implant for Zimmer Biomet's European customers. 5 As part of the U.S ...

Medical technology company Zimmer Biomet has received approval from the U.S. Food and Drug Administration for its Oxford cementless partial knee, making it the first implant of its kind available ...

Mike Zimmer had the Cowboys Defense playing great ball vs the Commanders 'Simpsons' voice actor is retiring after 35 years with the show These 5 Rare Quarters From Over 20 Years Ago Are Worth a ...

Zimmer Biomet earned FDA clearance for its Persona SoluTion porous plasma spray femur total knee implant component, according to a Dec. 4 news release.

(RTTNews) - Zimmer Biomet (ZBH) announced FDA 510(k) clearance of Persona SoluTion Porous Plasma Spray Femur, a total knee implant component offering an alternative for patients with sensitivities ...

Valued at $22.1 billion by market cap, Zimmer Biomet Holdings, Inc. (ZBH) is a medical technology company specializing in designing, manufacturing, and marketing orthopedic reconstructive products.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...